Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.55 |
| ▸ | PGR | P06401 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | ACLY | P53396 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491926 | 1.00 | NR3C1 (0.55) | NR3C1NR3C2PGRCYP3A4ACLY | |
| SCHEMBL3489572 | 0.76 | PGR (0.50) | NR3C1NR3C2PGRCYP3A4ACLY | |
| SCHEMBL3489898 | 0.73 | NR3C1 (0.44) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL3491178 | 0.72 | LMNA (0.52) | NR3C1NR3C2PGRCYP3A4ALDH1A1 | |
| SCHEMBL810628 | 0.72 | ACLY (0.46) | NR3C1NR3C2PGRCYP3A4ACLY | |
| SCHEMBL1287280 | 0.72 | ALDH1A1 (0.68) | CYP3A4ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL1287373 | 0.72 | ALDH1A1 (0.68) | CYP3A4ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL8988805 | 0.71 | NR3C1 (0.43) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL13744523 | 0.70 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2A | |
| SCHEMBL4216055 | 0.70 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OPRD1, HTR6, HTR1D | NR3C1 247/4885NR3C2 335/4885PGR 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.